Ads
related to: brief description of multiple sclerosis disease progression- Financial Resources
See Financial & Savings Info.
Learn About Savings Options.
- Treatment FAQs
See Frequently Asked
Questions. Get The Answers.
- Patient Stories
See What Real Patients
Are Saying About This Treatment.
- Patient Resources
Download Resources To
Learn More About Treatment.
- Relapsing MS Treatment
Learn About A RMS
Treatment Option.
- Getting Started
Sign Up For More Info On
How To Get Started.
- Financial Resources
Search results
Results From The WOW.Com Content Network
Currently it is unknown what the primary cause of MS is; if MS is a heterogeneous disease, the lesion development process would not be unique. In particular, some PPMS patients having a special clinical course named rapidly progressive multiple sclerosis could have a special genetic cause [47] and a different development process.
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease , MS disrupts the nervous system's ability to transmit signals , resulting in a range of signs and symptoms , including physical, mental , and sometimes psychiatric problems.
Main symptoms of multiple sclerosis Symptoms and findings in multiple sclerosis. Multiple sclerosis can cause a variety of symptoms varying significantly in severity and progression among individuals: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech or swallowing (), visual ...
For each of the four type of MS, early diagnosis and treatment are key to slowing its progression. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ...
Insidious neurological progression suggestive of MS (primary progressive MS) New criteria: One year of disease progression (retrospectively or prospectively determined) and two or three of the following: 1. Evidence for DIS in the brain based on 1 or more T2 lesions in the MS-characteristic (periventricular, juxtacortical, or infratentorial ...
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Ads
related to: brief description of multiple sclerosis disease progression